Fig. 2From: Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockadePartial response of metastatic basal cell carcinoma to pembrolizumab (anti-PD-1). Computed tomography (CT) scans performed pre-therapy (top row) and 6.5 months after initiating pembrolizumab (anti-PD-1, bottom row) demonstrate regression of basal cell carcinoma lung metastases. Yellow arrowheads indicate sites of metastasesBack to article page